Anti-Hu CD263 FITC

Anti-Hu CD263 FITC
Regulatory status
RUO
Antigen
CD263
Clone
TRAIL-R3-02
Format
FITC
Reactivity
Human
Application
Excitation laser
blue (488 nm)
Variant
0.1 mg
1F-518-C100
Ask for delivery term HERE
270.00 USD

0.025 mg
1F-518-C025
Delivery 1 week
135.00 USD
Variant
0.1 mg
11-261-C100
In stock
270.00 USD

0.1 mg
11-261-C100
In stock
135.00 USD
Product details
Description
References
Isotype
Mouse IgG1
Specificity
The antibody TRAIL-R3-02 reacts with TRAIL-R3, a 35 kDa GPI-anchored extracellular membrane protein expressed mainly on neutrophils.
Workshop
HLDA X
Application
Application details
Flow cytometry: Recommended dilution: 1-5 μg/ml.
Reactivity
Human
Immunogen
TRAIL-R3 (aa 1-280) - hIgGhc fusion protein
Concentration
0.1 mg/ml
Preparation
Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
TNFRSF10C, DcR1, TRAIL-R3, TRID, LIT
Antigen description
TRAIL-R3 (CD263, TR3, DcR1, LIT, TRID), expressed mainly on neutrophils, belongs to receptors of TRAIL, a TNF-like membrane cytotoxic protein that induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R3, however, is a GPI-anchored protein that lacks cytoplasmic death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by competing for binding of TRAIL with death receptor 5 (DR5).
Entrez Gene ID 8794
UniProt ID O14798

General references:

Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol Oncol Res. 2007;13(4):290-4.
PubMed
Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39(7-8):1462-75.
PubMed
Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006 Oct;26(19):7046-55.
PubMed
Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 May 25;5(1):54.
PubMed
Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18099-104.
PubMed
Variant
0.1 mg
1F-518-C100
Ask for delivery term HERE
270.00 USD

0.025 mg
1F-518-C025
Delivery 1 week
135.00 USD
Variant
0.1 mg
11-261-C100
In stock
270.00 USD

0.1 mg
11-261-C100
In stock
135.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
200.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
60.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
50.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
ApplicationFC, FC(IC)
0.1 mg
150.00 USD